Tuberculosis remains one of the most consequential infectious diseases in human history, yet its burden is unevenly distributed and deeply entangled with HIV status, drug resistance, and behavioral risk factors. At a moment when global health financing is contracting, a rigorous accounting of where TB stands — and how far treatment and prevention efforts have actually moved the needle — carries enormous practical weight for anyone tracking infectious disease and longevity at a population level.
This Global Burden of Disease 2023 analysis quantified TB mortality, morbidity, and disability-adjusted life-years (DALYs) across 204 countries and territories spanning 1990 to 2023. Using the Cause of Death Ensemble model alongside DisMod-MR 2.1, the researchers simultaneously modeled TB incidence, prevalence, and mortality stratified by age, sex, HIV co-infection status, and multidrug resistance. A comparative risk assessment framework isolated the population-attributable fractions for alcohol use, smoking, and elevated fasting plasma glucose — three modifiable exposures — providing a mechanistically richer picture than prior surveillance-based estimates. Progress toward the WHO End TB Strategy's twin targets — a 95% reduction in TB deaths and a 90% cut in incidence between 2015 and 2035 — was evaluated against observed trajectories.
This analysis sits within a long tradition of GBD TB reporting, but its 2023 iteration arrives at a critical inflection point: shrinking donor budgets and disrupted supply chains have reversed hard-won gains in several high-burden regions, making this pre-disruption baseline unusually consequential. The inclusion of MDR-TB stratified by HIV status is particularly valuable, as co-infected individuals face compounded treatment complexity and dramatically higher case fatality. The methodological strength here is the integration of verbal autopsy and minimally invasive tissue sampling data for settings with weak vital registration — historically a major source of uncertainty. Key limitations include the modeled (rather than directly observed) nature of many national estimates, and the inherent lag between real-world conditions and GBD data inputs. Still, for health-conscious adults, the risk-factor component is salient: alcohol, tobacco, and dysglycemia emerge as quantifiable TB amplifiers, suggesting that metabolic and lifestyle interventions have indirect but meaningful infectious-disease relevance. This is a confirmatory but exceptionally well-powered piece of global health surveillance.